Ildong Holdings Co., Ltd. (KRX: 000230)

Market Cap	92.71B
Revenue (ttm)	643.30B
Net Income (ttm)	-42.00B
Shares Out	11.29M
EPS (ttm)	-3,719.23
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (1.25%)
Ex-Dividend Date	n/a

Volume	16,712
Open	8,090.00
Previous Close	8,030.00
Day's Range	8,020.00 - 8,310.00
52-Week Range	6,570.00 - 12,220.00
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Ildong Holdings

Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer’s disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It is also involved in the research and manufacture of health foods and ingredients; and provides hyaluronic acid for use in drugs, medical devices, and cosmetics. In addition, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 78
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000230

Financial Performance

In 2023, Ildong Holdings's revenue was 638.45 billion, a decrease of -5.49% compared to the previous year's 675.54 billion. Losses were -59.59 billion, -41.78% less than in 2022.